Cargando…

Pregnancy Loss Signal from Prostaglandin Eye Drop Use in Pregnancy: A Disproportionality Analysis Using Japanese and US Spontaneous Reporting Databases

BACKGROUND: There is limited research regarding the use of glaucoma medicines during pregnancy. Prostaglandins contract uterine smooth muscle; however, it is not clear whether prostaglandin eye drops are associated with pregnancy loss in pregnant women. OBJECTIVES: We conducted a pharmacovigilance s...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Takamasa, Mori, Chiyo, Koshiba, Honoka, Yuminaga, Ryuta, Tanabe, Kouichi, Ohtsu, Fumiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844322/
https://www.ncbi.nlm.nih.gov/pubmed/34797554
http://dx.doi.org/10.1007/s40801-021-00287-y
_version_ 1784651447526227968
author Sakai, Takamasa
Mori, Chiyo
Koshiba, Honoka
Yuminaga, Ryuta
Tanabe, Kouichi
Ohtsu, Fumiko
author_facet Sakai, Takamasa
Mori, Chiyo
Koshiba, Honoka
Yuminaga, Ryuta
Tanabe, Kouichi
Ohtsu, Fumiko
author_sort Sakai, Takamasa
collection PubMed
description BACKGROUND: There is limited research regarding the use of glaucoma medicines during pregnancy. Prostaglandins contract uterine smooth muscle; however, it is not clear whether prostaglandin eye drops are associated with pregnancy loss in pregnant women. OBJECTIVES: We conducted a pharmacovigilance study using spontaneous report databases from Japan and the USA to evaluate the association between pregnancy loss and the use of prostaglandin eye drops during pregnancy. METHODS: The Japanese Adverse Drug Event Report database and the Food and Drug Administration Adverse Event Reporting System were used for analysis. Disproportionality analyses and a review of individual case safety reports were conducted. RESULTS: As for prostaglandin eye drops in pregnancy-related reports, there were eight reports involving latanoprost in the Japanese Adverse Drug Event Report database and no reports of pregnant women using other prostaglandin eye drops. In the Food and Drug Administration Adverse Event Reporting System, there were 25 reports involving latanoprost, 23 involving bimatoprost, 13 involving travoprost, and three involving tafluprost. The drug safety signal was detected during latanoprost usage and pregnancy loss. In the Japanese Adverse Drug Event Report database, there were five reports of pregnancy loss related to latanoprost, with a reporting odds ratio of 12.84 (95% confidence interval 3.06–53.86), and in the Food and Drug Administration Adverse Event Reporting System, pregnancy loss was reported in 12 cases of latanoprost usage with a reporting odds ratio of 4.35 (95% confidence interval 1.98–9.54). Uterine contractions were observed as concomitant adverse events in one case. CONCLUSIONS: Although a disproportionality analysis cannot determine causality, we need to keep an eye on the signal detected in this study. This signal should be validated using a causal design study.
format Online
Article
Text
id pubmed-8844322
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88443222022-02-23 Pregnancy Loss Signal from Prostaglandin Eye Drop Use in Pregnancy: A Disproportionality Analysis Using Japanese and US Spontaneous Reporting Databases Sakai, Takamasa Mori, Chiyo Koshiba, Honoka Yuminaga, Ryuta Tanabe, Kouichi Ohtsu, Fumiko Drugs Real World Outcomes Original Research Article BACKGROUND: There is limited research regarding the use of glaucoma medicines during pregnancy. Prostaglandins contract uterine smooth muscle; however, it is not clear whether prostaglandin eye drops are associated with pregnancy loss in pregnant women. OBJECTIVES: We conducted a pharmacovigilance study using spontaneous report databases from Japan and the USA to evaluate the association between pregnancy loss and the use of prostaglandin eye drops during pregnancy. METHODS: The Japanese Adverse Drug Event Report database and the Food and Drug Administration Adverse Event Reporting System were used for analysis. Disproportionality analyses and a review of individual case safety reports were conducted. RESULTS: As for prostaglandin eye drops in pregnancy-related reports, there were eight reports involving latanoprost in the Japanese Adverse Drug Event Report database and no reports of pregnant women using other prostaglandin eye drops. In the Food and Drug Administration Adverse Event Reporting System, there were 25 reports involving latanoprost, 23 involving bimatoprost, 13 involving travoprost, and three involving tafluprost. The drug safety signal was detected during latanoprost usage and pregnancy loss. In the Japanese Adverse Drug Event Report database, there were five reports of pregnancy loss related to latanoprost, with a reporting odds ratio of 12.84 (95% confidence interval 3.06–53.86), and in the Food and Drug Administration Adverse Event Reporting System, pregnancy loss was reported in 12 cases of latanoprost usage with a reporting odds ratio of 4.35 (95% confidence interval 1.98–9.54). Uterine contractions were observed as concomitant adverse events in one case. CONCLUSIONS: Although a disproportionality analysis cannot determine causality, we need to keep an eye on the signal detected in this study. This signal should be validated using a causal design study. Springer International Publishing 2021-11-19 /pmc/articles/PMC8844322/ /pubmed/34797554 http://dx.doi.org/10.1007/s40801-021-00287-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Sakai, Takamasa
Mori, Chiyo
Koshiba, Honoka
Yuminaga, Ryuta
Tanabe, Kouichi
Ohtsu, Fumiko
Pregnancy Loss Signal from Prostaglandin Eye Drop Use in Pregnancy: A Disproportionality Analysis Using Japanese and US Spontaneous Reporting Databases
title Pregnancy Loss Signal from Prostaglandin Eye Drop Use in Pregnancy: A Disproportionality Analysis Using Japanese and US Spontaneous Reporting Databases
title_full Pregnancy Loss Signal from Prostaglandin Eye Drop Use in Pregnancy: A Disproportionality Analysis Using Japanese and US Spontaneous Reporting Databases
title_fullStr Pregnancy Loss Signal from Prostaglandin Eye Drop Use in Pregnancy: A Disproportionality Analysis Using Japanese and US Spontaneous Reporting Databases
title_full_unstemmed Pregnancy Loss Signal from Prostaglandin Eye Drop Use in Pregnancy: A Disproportionality Analysis Using Japanese and US Spontaneous Reporting Databases
title_short Pregnancy Loss Signal from Prostaglandin Eye Drop Use in Pregnancy: A Disproportionality Analysis Using Japanese and US Spontaneous Reporting Databases
title_sort pregnancy loss signal from prostaglandin eye drop use in pregnancy: a disproportionality analysis using japanese and us spontaneous reporting databases
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844322/
https://www.ncbi.nlm.nih.gov/pubmed/34797554
http://dx.doi.org/10.1007/s40801-021-00287-y
work_keys_str_mv AT sakaitakamasa pregnancylosssignalfromprostaglandineyedropuseinpregnancyadisproportionalityanalysisusingjapaneseandusspontaneousreportingdatabases
AT morichiyo pregnancylosssignalfromprostaglandineyedropuseinpregnancyadisproportionalityanalysisusingjapaneseandusspontaneousreportingdatabases
AT koshibahonoka pregnancylosssignalfromprostaglandineyedropuseinpregnancyadisproportionalityanalysisusingjapaneseandusspontaneousreportingdatabases
AT yuminagaryuta pregnancylosssignalfromprostaglandineyedropuseinpregnancyadisproportionalityanalysisusingjapaneseandusspontaneousreportingdatabases
AT tanabekouichi pregnancylosssignalfromprostaglandineyedropuseinpregnancyadisproportionalityanalysisusingjapaneseandusspontaneousreportingdatabases
AT ohtsufumiko pregnancylosssignalfromprostaglandineyedropuseinpregnancyadisproportionalityanalysisusingjapaneseandusspontaneousreportingdatabases